Targeting mitochondrial metabolism to improve lung cancer treatment
Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial Metabolism
This study is looking at how a common drug called papaverine might help lung cancer patients by making their tumors use less oxygen, which could make treatments like radiation and immunotherapy work better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10911262 on NIH RePORTER |
What this research studies
This research investigates how to overcome the challenges posed by low oxygen levels in tumors, known as hypoxia, which can hinder the effectiveness of cancer therapies like radiation and immunotherapy. The team is exploring the use of an FDA-approved drug, papaverine, which can reduce oxygen consumption in cancer cells, potentially enhancing treatment outcomes. By focusing on decreasing the demand for oxygen rather than increasing its supply, the researchers aim to improve the response of lung cancer patients to existing therapies. The study includes preclinical models to evaluate the effectiveness of this approach in enhancing immune responses against tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are lung cancer patients experiencing hypoxia and who have not responded adequately to conventional treatments.
Not a fit: Patients with lung cancer who do not exhibit hypoxia or those who are in advanced stages of the disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for lung cancer patients, particularly those who currently do not respond well to standard therapies.
How similar studies have performed: While the approach of targeting mitochondrial metabolism is innovative, similar strategies have shown promise in preclinical studies, indicating potential for success.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Denko, Nicholas C. — Ohio State University
- Study coordinator: Denko, Nicholas C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.